Watch the virtual breakout session featuring James Brady, PhD, Senior Vice President of Technical Applications at MaxCyte, as he presents on how electroporation is an effective tool in engineering scalable cell therapies. Learn about the power of #CRISPR technology in precisely modifying genes for therapeutic purposes and more. https://bit.ly/4cshbmL
MaxCyte, Inc.’s Post
More Relevant Posts
-
🔬 Exciting news for all biotech enthusiasts! 🧬 Kalorama's comprehensive Cell Therapy and Gene Therapy Markets report is now available for purchase, providing in-depth insights and analysis to help you stay ahead! From market summaries to competitive analyses, our report covers it all. Don't miss out on this valuable resource that can help shape your strategic decisions and drive business success. 🌟 #Biotech #CellTherapy #GeneTherapy #CGT #MarketReport #BusinessInsights 🔍 Explore our findings: https://hubs.la/Q02x744g0
To view or add a comment, sign in
-
Our focus on #innovation will not be shaken! If you are onsite at the European Society of Gene and Cell Therapy Congress, head to the Gale Maritime Room to check out Heiko von der Leyen representing the team by presenting our poster P353: A concept of decentralized point-of care manufacturing of #cellandgenetherapy – #technical and #regulatory considerations.
To view or add a comment, sign in
-
Transduction of cells with lentiviruses has not been as convenient and uncomplicated as it can be with the use of Takara Lenti-X Transduction Sponge! The process involves simply adding a mixture of virus and cells onto the sponge and allowing for incubation. The sponge acts as a microfluidic transduction enhancer, bringing cells and viruses in close proximity during incubation and then dissolving upon subsequent centrifugation. As a result, the efficiency of transduction is enhanced with a more convenient and user-friendly method. For more info check related Takara Bio Europe webpages: https://lnkd.in/dwxNmfDb https://lnkd.in/dYr5N7Xc Contact us: info@gen-era.com.tr #lentivirus #transduction #Takara #LentiX #sponge #microfluidic
A transformative technology for simplified yet dependable lentiviral transduction in the gene and cell therapy space is here! https://ow.ly/OvbW50Ru15Y Today we announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable #microfluidic transduction enhancer. Made from calcium-crosslinked alginate, it resolves common limitations in #lentiviral transductions with its easy-to-use workflow. Use to increase your transduction efficiency while preserving cellular phenotype resulting in high cell viability. The Lenti-X™ Transduction Sponge will provide you with a completely new way to engineer even hard-to-transduce #cells and advance your downstream applications. Visit us at #ASGCT2024 booth #2259 and #ISCT2024 booth #721 to view the product.
To view or add a comment, sign in
-
Advancements in Gene and Cell Therapy have profound impact on life sciences industry. These advancements have opened up: 1. New avenues for treatment, 2. Spurred research and investment, 3. Facilitated collaboration, 4. Propelled the shift towards personalized medicine. As the field continues to evolve, it is expected to further shape the future of lifesciences industry worldwide 🌐. #lifesciences #lifescienceindustry #genetherapy #celltherapy #cellandgenetherapy #healthcare #healthcareinnovation #research #researchanddevelopment #revolution
To view or add a comment, sign in
-
Our focus on #innovation will not be shaken! If you are onsite at the European Society of Gene and Cell Therapy Congress, head to the Gale Maritime Room to check out Heiko von der Leyen representing the team by presenting our poster P353: A concept of decentralized point-of care manufacturing of #cellandgenetherapy – #technical and #regulatory considerations.
To view or add a comment, sign in
-
Principal & Advanced Therapies Practice Lead, DeciBio Consulting; Investor, BioTools Fund; Founder / Director, Suono Bio
What is top of mind across cell therapy?... While ISCT, International Society for Cell & Gene Therapy annual meeting is in the rearview, the highlights, key trends, and hurdles remain! We asked stakeholders from companies like Ori Biotech, xcellbio, and uBriGene Biosciences Inc., and investors from AVANT BIO what their key takeaways are. Check it out here: 👉 https://lnkd.in/dEUWbKAi The long and short, you ask? 1️⃣ Manufacturing Innovations and Challenges: The field is rapidly advancing with new automated platforms to address current suboptimal workflows. 2️⃣ Technological Advancements and Excitement: The conference saw multiple launches of new systems, like Ori's IRO®, Cytiva's enhanced Sefia system, and Xcellbio's AVATAR. 3️⃣ Focus on Potency and Data-Driven Processes: There was a strong emphasis on developing better potency assessments and leveraging data-driven processes. Did you attend the conference? What was your key takeaway? Let me know! #celltherapy #pharma #healthcare
To view or add a comment, sign in
-
Innovating drug discovery & cell therapy with iPSCs | Senior Director of BD @ Ncardia | Follow for daily content, from science to business
Long conference, but a good one! American Society of Gene & Cell Therapy #genetherapy #celltherapy #drugdiscovery Hi, I'm Jeff Bissen (pronounced BEE-sen) 👋 I have 10 years of biotech experience, and I post almost every weekday about both the science and business sides of the industry. Interested? Follow my profile 🔔 And subscribe to my weekly newsletter: https://lnkd.in/e8r_WBP8 *** Views expressed in my newsletter are entirely my own and not necessarily held by any past, present, or future employer***
To view or add a comment, sign in
-
Think ahead: preparing for challenges to accelerate your #celltherapycommercialization For successful commercialization of #CARTcelltherapies, it is critical to establish a cost-effective and reliable manufacturing process. Next month, Saba Ghassemi (Assistant Professor, Center for Cellular Immunotherapies, University of Pennsylvania), Sabrina Carmichael (Fast Trak Global Technical Leader, Cytiva), Hannah Song (Biologist, Product Development, NIH Center for Cellular Engineering), and Kathryn Henckels (Associate Director, Cell & Gene Therapy API, Johnson & Johnson) will discuss how decisions made during the early stages of process development can have long-lasting effects. Register for this #webinar below:
Online Event
To view or add a comment, sign in
-
Think ahead: preparing for challenges to accelerate your #celltherapycommercialization Later this month, Saba Ghassemi (Assistant Professor, Center for Cellular Immunotherapies, University of Pennsylvania), Sabrina Carmichael (Fast Trak Global Technical Leader, Cytiva), Hannah Song (Biologist, Product Development, NIH Center for Cellular Engineering), and Kathryn Henckels (Associate Director, Cell & Gene Therapy API, Johnson & Johnson) will discuss how decisions made during the early stages of process development can have long-lasting effects. Attend this webinar to learn about: • Establishing a cost-effective and reliable manufacturing process • The benefits of implementing the appropriate closed and automated process during early clinical trials • Critical factors necessary for the successful commercialization of an advanced therapy Register for this #webinar below:
Online Event
To view or add a comment, sign in
-
Hear from our scientist, Federica Tomay, about addressing challenges in cell therapy manufacturing as production scales up and innovative technologies that can overcome some of these challenges to produce more efficient, accessible, and affordable cell-based therapies. In the article published by BioSpectrum Asia, Federica highlights the essential tools which are instrumental in refining the process of genetically modifying patient cells. Read more: https://bit.ly/4ahUe4E #Agilent. #CellAnalysis. #BringGreatScienceToLife.
To view or add a comment, sign in
8,387 followers